CADL net incomeQ2 2026-$38.91M
CADL net income was -$38.91M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.80M a year earlier. For the full fiscal 2025 it was -$38.18M, compared with -$55.18M in fiscal 2024.
Candel Therapeutics Inc. (CADL) financials
For the twelve months ended Jun 30, 2026, Candel Therapeutics Inc. reported -$88.53M of net income.
- Net income, TTM
- -$88.53M
- Free cash flow, TTM
- -$57.32M
- EPS, diluted, TTM
- -$1.42
- Cash
- $201.56M
- Market cap
- $726.2M
FY2020FY2022
FY2020FY2025
FY2020FY2025
CADL revenue and earnings growth
CADL EPSQ2 2026-$0.52
CADL diluted EPS was -$0.52 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.72.
CADL free cash flowQ2 2026-$17.25M
CADL free cash flow was -$17.25M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.92M a year earlier. For the full fiscal 2025 it was -$38.90M, compared with -$27.04M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $125.0K | $125.0K | $125.0K |
| Research and development | $30.50M | $19.31M | $24.51M | $20.79M | $15.18M | $8.75M |
| Selling, general and admin | $17.77M | $14.06M | $13.88M | $14.06M | $10.67M | $5.18M |
| Operating income | -$48.27M | -$33.37M | -$38.39M | -$34.72M | -$25.73M | -$13.81M |
| Interest expense | $2.12M | $2.09M | -$2.60M | $1.71M | - | - |
| Pre-tax income | -$38.18M | -$55.18M | - | - | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | - |
| Net income | -$38.18M | -$55.18M | -$37.94M | -$18.79M | -$36.12M | -$17.68M |
| EPS, basic | -$0.72 | -$1.74 | -$1.31 | -$0.65 | -$1.91 | -$1.52 |
| EPS, diluted | -$0.72 | -$1.74 | -$1.31 | -$0.65 | -$1.91 | -$1.52 |
| Diluted shares | 53.0M | 31.7M | 28.9M | 28.8M | 18.9M | 11.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $119.73M | $102.92M | $35.68M | $70.32M | $83.07M | $35.32M |
| Current assets | $121.39M | $103.80M | $36.80M | $71.94M | $84.94M | $35.15M |
| Total assets | $125.19M | $106.87M | $41.20M | $77.69M | $89.20M | $38.28M |
| Current liabilities | $9.00M | $37.53M | $14.18M | $5.62M | $5.36M | $4.71M |
| Short-term debt | $0 | $9.89M | $8.89M | - | - | - |
| Long-term debt | - | $1.73M | $11.63M | - | - | - |
| Total debt | - | $11.63M | $20.52M | - | $560.0K | $483.0K |
| Total liabilities | $73.27M | $40.54M | $28.46M | $29.98M | $25.07M | $12.78M |
| Shareholders' equity | $51.92M | $66.33M | $12.74M | $47.71M | $64.14M | -$23.56M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$38.31M | -$27.02M | -$34.24M | -$31.42M | -$22.22M | -$9.07M |
| Capital expenditures | $587.0K | $16.0K | $457.0K | $1.30M | $1.83M | $1.48M |
| Free cash flow | -$38.90M | -$27.04M | -$34.70M | -$32.72M | -$24.05M | -$10.55M |
| Investing cash flow | -$560.0K | -$16.0K | -$280.0K | -$1.30M | -$1.83M | $38.45M |
| Financing cash flow | $56.10M | $94.28M | -$121.0K | $19.97M | $71.80M | $490.0K |
| Stock-based compensation | $3.82M | $5.31M | $3.09M | $2.31M | $2.96M | $2.11M |
| Depreciation and amortization | - | - | - | $778.0K | $232.0K | $91.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | 0.0% | 0.0% | - |
| Operating margin | - | - | - | -27777.6% | -20580.8% | -11048.0% |
| Net margin | - | - | - | -15035.2% | -28899.2% | -14144.0% |
| Free cash flow margin | - | - | - | -26172.8% | -19242.4% | -8437.6% |
| Return on equity | -73.5% | -83.2% | -297.7% | -39.4% | -56.3% | - |
| Return on assets | -30.5% | -51.6% | -92.1% | -24.2% | -40.5% | -46.2% |
| Current ratio | 13.49 | 2.77 | 2.59 | 12.81 | 15.84 | 7.46 |
| Debt to equity | - | 0.18 | 1.61 | - | 0.01 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $19.80M | $9.84M | $11.03M | $8.46M | $6.99M | $4.02M | $4.82M | $5.42M | $4.98M | $4.10M | $7.26M | $5.84M |
| Selling, general and admin | $6.95M | $6.44M | $4.72M | $4.75M | $4.19M | $4.11M | $3.32M | $3.34M | $3.59M | $3.80M | $3.06M | $3.02M |
| Operating income | -$26.75M | -$16.28M | -$15.75M | -$13.21M | -$11.18M | -$8.13M | -$8.14M | -$8.76M | -$8.57M | -$7.90M | -$10.32M | -$8.86M |
| Interest expense | $1.57M | $1.56M | $1.42M | $161.0K | $236.0K | $306.0K | $390.0K | $487.0K | $567.0K | $646.0K | -$4.52M | $669.0K |
| Income tax | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Net income | -$38.91M | -$8.86M | -$29.50M | -$11.27M | -$4.80M | $7.38M | -$14.07M | -$10.65M | -$22.24M | -$8.22M | -$11.10M | -$8.44M |
| EPS, basic | -$0.52 | -$0.14 | -$0.57 | -$0.21 | -$0.09 | $0.15 | -$0.39 | -$0.33 | -$0.74 | -$0.28 | -$0.39 | -$0.29 |
| EPS, diluted | -$0.52 | -$0.14 | -$0.55 | -$0.21 | -$0.09 | $0.13 | -$0.39 | -$0.33 | -$0.74 | -$0.28 | -$0.39 | -$0.29 |
| Diluted shares | 74.1M | 62.4M | - | 54.9M | 51.5M | 54.8M | - | 32.0M | 29.9M | 29.2M | - | 28.9M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $201.56M | $194.83M | $119.73M | $86.96M | $100.95M | $92.43M | $102.92M | $16.82M | $21.72M | $25.98M | $35.68M | $43.25M |
| Current assets | $204.16M | $197.75M | $121.39M | $90.13M | $103.61M | $93.15M | $103.80M | $18.09M | $22.73M | $27.14M | $36.80M | $45.10M |
| Total assets | $208.15M | $201.92M | $125.19M | $93.60M | $105.97M | $95.91M | $106.87M | $21.52M | $26.48M | $31.22M | $41.20M | $50.06M |
| Current liabilities | $12.69M | $7.05M | $9.00M | $10.93M | $14.71M | $20.07M | $37.53M | $15.27M | $14.00M | $13.54M | $14.18M | $10.33M |
| Short-term debt | - | - | $0 | $4.22M | $6.70M | $9.17M | $9.89M | $9.85M | $9.81M | $9.77M | $8.89M | $6.10M |
| Long-term debt | - | - | - | - | - | - | $1.73M | $4.22M | $6.71M | $9.17M | $11.63M | $14.34M |
| Total debt | - | - | - | - | - | - | $11.63M | $14.08M | $16.51M | $18.94M | $20.52M | $20.44M |
| Total liabilities | $82.02M | $63.89M | $73.27M | $13.47M | $15.76M | $21.23M | $40.54M | $36.77M | $36.46M | $25.24M | $28.46M | $27.04M |
| Shareholders' equity | $126.13M | $138.03M | $51.92M | $80.12M | $90.21M | $74.67M | $66.33M | -$15.26M | -$9.97M | $5.98M | $12.74M | $23.02M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.18M | -$18.04M | -$10.57M | -$10.24M | -$8.89M | -$8.62M | -$5.81M | -$6.57M | -$6.20M | -$8.44M | -$7.42M | -$8.81M |
| Capital expenditures | $69.0K | $675.0K | $409.0K | $144.0K | $31.0K | $3.0K | $3.0K | $0 | $6.0K | $7.0K | $47.0K | $103.0K |
| Free cash flow | -$17.25M | -$18.71M | -$10.98M | -$10.38M | -$8.92M | -$8.62M | -$5.82M | -$6.57M | -$6.20M | -$8.45M | -$7.47M | -$8.91M |
| Investing cash flow | -$69.0K | -$675.0K | -$409.0K | -$117.0K | -$31.0K | -$3.0K | -$3.0K | $0 | -$6.0K | -$7.0K | -$27.0K | -$103.0K |
| Financing cash flow | $23.98M | $93.81M | $43.90M | -$3.37M | $17.44M | -$1.87M | $91.91M | $1.68M | $1.95M | -$1.25M | -$121.0K | $0 |
| Stock-based compensation | $2.86M | $1.45M | $1.29M | $1.16M | $1.05M | $314.0K | $1.24M | $1.18M | $1.84M | $1.04M | $939.0K | $686.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 16.09 | 28.05 | 13.49 | 8.25 | 7.04 | 4.64 | 2.77 | 1.18 | 1.62 | 2.00 | 2.59 | 4.37 |
| Debt to equity | - | - | - | - | - | - | 0.18 | - | - | 3.17 | 1.61 | 0.89 |
Source: XBRL data Candel Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CADL peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CADL | - | - | -$88.53M | - | $726.2M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
CADL FAQ
6 questionsIs CADL profitable?
No. Candel Therapeutics Inc. reported a net loss of $88.53M for the twelve months ended Jun 30, 2026.How much cash and debt does CADL have?
Candel Therapeutics Inc. reported $201.56M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CADL free cash flow?
Candel Therapeutics Inc. generated -$57.32M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$56.02M less capital expenditures.What is CADL earnings per share?
Diluted earnings per share were -$1.42 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did CADL last report financial results?
The latest statements here come from Candel Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this CADL financial data come from?
Quantisnow builds these statements from the structured XBRL data Candel Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.